Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2020 07:30 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in potential milestones, and tiered double-digit royaltiesEntered into research...
August 03, 2020 16:05 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
August 03, 2020 08:15 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
July 30, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter Financial Results and Recent Operational Highlights

WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
July 28, 2020 06:00 ET | Source: Selecta Biosciences, Inc.

Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

STOCKHOLM, Sweden and WATERTOWN, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the strategic licensing agreement with Selecta...
June 18, 2020 08:30 ET | Source: Selecta Biosciences, Inc.

Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases

CAMBRIDGE, Mass. and WATERTOWN, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, and Selecta Biosciences,...
June 15, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Raymond James 2020 Human Healthcare Innovation Conference

WATERTOWN, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
June 11, 2020 17:15 ET | Source: Selecta Biosciences, Inc.

Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

- Strategic licensing agreement for SEL-212, a unique phase 3-ready therapy powered by Selecta’s breakthrough immune tolerance platform, ImmTOR™, with the potential to fulfil a significant unmet need...
May 26, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Jefferies Virtual Healthcare Conference

WATERTOWN, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
May 07, 2020 07:30 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports First Quarter 2020 Financial Results

- Topline data announcement from the ongoing head-to-head COMPARE trial of SEL-212 remains on schedule for Q3 2020 - - Phase 3 clinical program of SEL-212 to commence in 2H 2020 - - Ongoing COVID-19...